Medical Technology

Current search: " boston top stories "

@xconomy.com 3 days ago

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

@xconomy.com 4 days ago

Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

@xconomy.com 12 days ago

Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue

@xconomy.com 16 days ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 17 days ago

Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More

@xconomy.com 18 days ago

Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally

@xconomy.com 26 days ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 1 month ago

AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact

@xconomy.com 2 months ago

Two Days, Six IPOs, and $1B Raised for Biotech Research & More

@xconomy.com 2 months ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 2 months ago

Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later

@xconomy.com 3 months ago

CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”

@xconomy.com 4 months ago

HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic

@xconomy.com 4 months ago

Join us this Wednesday for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 4 months ago

Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 4 months ago

Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 4 months ago

Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs

@xconomy.com 4 months ago

Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 4 months ago

Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses

@xconomy.com 4 months ago

Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 4 months ago

Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 5 months ago

Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health

@xconomy.com 5 months ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 7 months ago

EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device

@xconomy.com 7 months ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 7 months ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 7 months ago

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

@xconomy.com 7 months ago

Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More

@xconomy.com 7 months ago

With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14

@xconomy.com 7 months ago

Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus

@xconomy.com 8 months ago

Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers

@xconomy.com 8 months ago

Schrödinger Sets Course for IPO to Support Growing Internal Pipeline

@xconomy.com 8 months ago

Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy

@xconomy.com 8 months ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 9 months ago

Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal

@xconomy.com 10 months ago

Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B

@xconomy.com 10 months ago

Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug

@xconomy.com 10 months ago

Disc Medicine Launches With $50M to Advance New Anemia Treatments